This test is used to assess the expression levels of ER, PR, HER2/neu, Ki67, and p53 proteins in cancer tissue samples. IHC staining helps determine the hormone receptor status (ER/PR) and HER2/neu status of the tumor. These results guide treatment decisions, such as hormone therapy for ER/PR-positive tumors or targeted therapy (e.g., trastuzumab) for HER2/neu-positive tumors. By providing information about the protein expression levels, this test enables personalized therapy selection and improves treatment outcomes in breast and other cancers.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.